Chronic Antidepressant Treatment Impairs the Acquisition of Fear Extinction
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background Like fear conditioning, the acquisition phase of extinction involves new learning that is mediated by the amygdala. During extinction training, the conditioned stimulus is repeatedly presented in the absence of the unconditioned stimulus and the expression of previously learned fear gradually becomes suppressed. Our previous study revealed that chronic treatment with a selective serotonin reuptake inhibitor (SSRI) impairs the acquisition of auditory fear conditioning. To gain further insight into how SSRIs affect fear learning, we tested the effects of chronic SSRI treatment on the acquisition of extinction. Methods Rats were treated chronically (22 days) or subchronically (9 days) with the SSRI citalopram (10 mg/kg/day) before extinction training. The results were compared to those following chronic and subchronic treatment with tianeptine (10 mg/kg/day), an antidepressant with a different method of action. The expression of the NR2B subunit of the NMDA receptor in the amygdala was examined after behavioral testing. Results Chronic but not subchronic administration of citalopram impaired the acquisition of extinction and downregulated the NR2B subunit of the NMDA receptor in the lateral and basal nuclei of the amygdala. Similar behavioral and molecular changes were found with tianeptine treatment. Conclusions These results provide further evidence that chronic antidepressant treatment can impair amygdala-dependent learning. Our findings are consistent with a role for glutamatergic neurotransmission in the final common pathway of antidepressant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535 · cited 1×
“distinct biophysical and pharmacological properties of the receptor (61,62).”
BackgroundDifferential contribution of amygdala and hippocampus to cued and contextual fear conditioning.
Phillips, R. G., & LeDoux, J. E. (1992) · Behavioral Neuroscience · doi:10.1037/0735-7044.106.2.274 · Cited by 3,292
Self-citationMolecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Context, ambiguity, and unlearning: sources of relapse after behavioral extinction
Bouton, M. E. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01546-9 · Cited by 1,662
The lateral amygdaloid nucleus: sensory interface of the amygdala in fear conditioning
LeDoux, J., Cicchetti, P., Xagoraris, A., & Romanski, L. (1990) · The Journal of Neuroscience · doi:10.1523/jneurosci.10-04-01062.1990 · Cited by 1,167
Self-citationMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 1×
“NR2B subunit is sufficient to produce an antidepressant response (79,81,82) and anxiolytic-like effects in animals (79).”
BackgroundRessler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Self-citationSwitching on and off fear by distinct neuronal circuits
Herry, C., Ciocchi, S., Senn, V., Demmou, L., Müller, C., & Lüthi, A. (2008) · Nature · doi:10.1038/nature07166 · Cited by 950 · cited 2×
“A subset of cells in the basal nucleus shows an increase in CS-evoked activity during extinction training (54).”
BackgroundMiserendino, M. J. D., Sananes, C. B., Melia, K. R., & Davis, M. (1990) · Nature · doi:10.1038/345716a0 · Cited by 824
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
NMDA Receptor Subunit Composition Controls Synaptic Plasticity by Regulating Binding to CaMKII
Barria, A., & Malinow, R. (2005) · Neuron · doi:10.1016/j.neuron.2005.08.034 · Cited by 709
Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala
Falls, W., Miserendino, M., & Davis, M. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-03-00854.1992 · Cited by 673
Kim, J. J., Rison, R. A., & Fanselow, M. S. (1993) · Behavioral Neuroscience · doi:10.1037/0735-7044.107.6.1093 · Cited by 615
Drevets, W. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00102-5 · Cited by 581
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560
Neuroimaging Abnormalities in the Amygdala in Mood Disorders
DREVETS, W. C. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07098.x · Cited by 544
Furmark, T., Tillfors, M., Marteinsdottir, I., Fischer, H., Pissiota, A., Långström, B., & Fredrikson, M. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.425 · Cited by 530
Marks, I. M., Swinson, R. P., Başoǧlu, M., Kuch, K., Noshirvani, H., O'Sullivan, G., Lelliott, P. T., Kirby, M., McNamee, G., Sengun, S., et al. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.6.776 · Cited by 478 · cited 1×
“For example, when panic disorder patients were evaluated after treatment discontinuation, the outcome of those previously treated with CBT and imipramine (32) or alprazolam (33) was worse than patients who received CBT alone.”
ResultMouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic
Blanchard, D. (2001) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00009-4 · Cited by 461
Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues
Harmer, C. J., Mackay, C. E., Reid, C. B., Cowen, P. J., & Goodwin, G. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.015 · Cited by 450
Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placeboin Generalized Social Phobia
Davidson, J. R. T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., & Gadde, K. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.10.1005 · Cited by 415
McEwen, B. S., Chattarji, S., Diamond, D. M., Jay, T. M., Reagan, L. P., Svenningsson, P., & Fuchs, E. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.80 · Cited by 406 · cited 1×
“Instead, the effects of tianeptine have been linked to changes in the glutamatergic system (44,45).”
BackgroundSelf-citationFear erasure in mice requires synergy between antidepressant drugs and extinction training
Karpova, N. N., Pickenhagen, A., Lindholm, J., Tiraboschi, E., Kulesskaya, N., Ágústsdóttir, A., Antila, H., Popova, D., Akamine, Y., Sullivan, R., et al. (2011) · Science · doi:10.1126/science.1214592 · Cited by 382
Augmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive Disorder
Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050776 · Cited by 358
Rodrigues, S. M., Schafe, G. E., & LeDoux, J. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06889.2001 · Cited by 350 · cited 2×
“conditioning and the acquisition of extinction, without affecting expression of the fear memory (20,21).”
BackgroundSelf-citationGuastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., & Dadds, M. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.011 · Cited by 326
Exposure therapy for posttraumatic stress disorder
Rothbaum, B. O., & Schwartz, A. C. (2002) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.2002.56.1.59 · Cited by 313 · cited 1×
“Extinction-based cognitive behavioral therapy (CBT) is widely used in the treatment of anxiety disorders (22,23), during which patients systematically confront feared objects, situations, autonomic responses, or memories in the absence of an aversive event.”
BackgroundLin, C.-H., Yeh, S.-H., Lu, H.-Y., & Gean, P.-W. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-23-08310.2003 · Cited by 251
Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder
Otto, M. W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., Hofmann, S. G., Eisenmenger, K., Krystal, J. H., & Pollack, M. H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.036 · Cited by 251
VAN BALKOM, A. J. L. M., DE HAAN, E., VAN OPPEN, P., SPINHOVEN, P., HOOGDUIN, K. A. L., & VAN DYCK, R. (1998) · The Journal of Nervous & Mental Disease · doi:10.1097/00005053-199808000-00007 · Cited by 250
Serotonin 5-HT1A Receptors Regulate NMDA Receptor Channels through a Microtubule-Dependent Mechanism
Yuen, E. Y. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1187-05.2005 · Cited by 225 · cited 1×
“involvement of the 5-HT1A and 5-HT2A receptors (70,71).”
BackgroundFoa, E. B., Franklin, M. E., & Moser, J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01552-4 · Cited by 219
A History of Corticosterone Exposure Regulates Fear Extinction and Cortical NR2B, GluR2/3, and BDNF
Gourley, S. L., Kedves, A. T., Olausson, P., & Taylor, J. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.123 · Cited by 218 · cited 1×
“tion of extinction tested with contextual fear conditioning (105).”
MethodOugrin, D. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-200 · Cited by 201
Escitalopram effects on insula and amygdala BOLD activation during emotional processing
Arce, E., Simmons, A. N., Lovero, K. L., Stein, M. B., & Paulus, M. P. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1004-8 · Cited by 198
Burghardt, N. S., Bush, D. E. A., McEwen, B. S., & LeDoux, J. E. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.023 · Cited by 179
Self-citationExposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial
Haug, T. T., Blomhoff, S., Hellstrøm, K., Holme, I., Humble, M., Madsbu, H. P., & Wold, J. E. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.4.312 · Cited by 151
Franklin, M. E., Abramowitz, J. S., Bux, D. A., Zoellner, L. A., & Feeny, N. C. (2002) · Professional Psychology: Research and Practice · doi:10.1037/0735-7028.33.2.162 · Cited by 90
Otto, M. W., McHugh, R. K., & Kantak, K. M. (2010) · Clinical Psychology Science and Practice · doi:10.1111/j.1468-2850.2010.01198.x · Cited by 87 · cited 3×
“Such a change in internal state provides one potential explanation for why any advantage of combined treatment is lost upon discontinuation of medication (40).”
BackgroundVan Apeldoorn, F. J., Van Hout, W. J. P. J., Mersch, P. P. A., Huisman, M., Slaap, B. R., Hale, W. W., Visser, S., Van Dyck, R., & Den Boer, J. A. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01157.x · Cited by 65
Cited by
From Pavlov to PTSD: The extinction of conditioned fear in rodents, humans, and anxiety disorders
VanElzakker, M. B., Kathryn Dahlgren, M., Caroline Davis, F., Dubois, S., & Shin, L. M. (2014) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.11.014 · Cited by 482
Multicenter Pilot Treatment Trial for Psychogenic Nonepileptic Seizures: A Randomized Clinical Trial
LaFrance, W. C., Baird, G. L., Barry, J. J., Blum, A. S., Frank Webb, A., Keitner, G. I., Machan, J. T., Miller, I., & Szaflarski, J. P. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.817 · Cited by 440
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“Subchronic citalopram (SSRI, 9d) No effect ns ns ip (Burghardt et al. 2013)”
BackgroundMataix-Cols, D., Fernández de la Cruz, L., Monzani, B., Rosenfield, D., Andersson, E., Pérez-Vigil, A., Frumento, P., de Kleine, R. A., Difede, J., Dunlop, B. W., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3955 · Cited by 288
Young, M. B., Norrholm, S. D., Khoury, L. M., Jovanovic, T., Rauch, S. A. M., Reiff, C. M., Dunlop, B. W., Rothbaum, B. O., & Howell, L. L. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4684-8 · Cited by 108
“acute nor chronic treatment with citalopram enhances fear memory extinction (Burghardt et al. 2013; Gunduz-Cinar et al. 2016).”
Background
Metadata
- Authors
- Burghardt, N. S., Sigurdsson, T., Gorman, J. M., McEwen, B. S., & LeDoux, J. E.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 73
- Issue
- 11
- Pages
- 1078-1086
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2069825985
- Cited by
- 88
- References
- 45
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.